Jessica Hergert

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

Saad Z. Usmani, MD, FACP, discusses various induction regimens and what they mean for patients with multiple myeloma.

Alison J. Moskowitz, MD, discusses pivotal data for brentuximab vedotin in Hodgkin and T-Cell Lymphoma, as well as other ongoing developments in these paradigms.

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

Kathryn E. Beckermann, MD, PhD, discusses the available single-agent and combination options for the treatment of patients with metastatic renal cell carcinoma.

Daniel A. Barocas, MD, MPH, FACS, discusses the CEASAR study in prostate cancer, as well as therapeutic updates in renal cell carcinoma.

Sergio A. Giralt, MD, discusses the changing frontline treatment setting in multiple myeloma, how to determine transplant eligibility, and the utility of testing for minimal residual disease negativity.

Everett E. Vokes, MD, discusses remaining questions in stage III non–small cell lung cancer following the PACIFIC results.

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

Kurt W. Tauer, MD, FACP, discusses encouraging updates across the spectrum of breast cancer subtypes.

Lawrence E. Feldman, MD, discusses the impact of the phase III data of the IMpower133 and CASPIAN trials, ongoing trials, and other updates in small cell lung cancer treatment.

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.

Isabel Preeshagul, DO, MBS, discusses encouraging updates with molecular drivers in non–small cell lung cancer and her advice to community oncologists treating patients.

Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.

Gregory M. M. Videtic, MD, CM, FRCPC, discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Lakshmi N. Rajdev, MD, discusses classifying and grading neuroendocrine tumors (NETs), treating patients with NETs, and novel therapeutic strategies in the pipeline.

Gregory J. Riely, MD, PhD, discusses the current treatment landscape for ALK- and ROS1-positive non–small cell lung cancer.

Pradnya D. Patil, MD, FACP, discusses the implications of these trials and the growing role of immunotherapy in lung cancer.

James P. Stevenson, MD, discusses available biomarker-driven therapies in non–small cell lung cancer, as well as rarer biomarkers under clinical investigation.

Liza C. Villaruz, MD, discusses the data with immunotherapy in squamous non–small cell lung cancer.

Heather H. Cheng, MD, PhD, discusses the GENTleMEN trial and the widening role of genetic testing for patients with prostate cancer.

Robert J. Kreitman, MD, discusses the role of minimal residual disease (MRD) status in hairy cell leukemia, how to effectively test for MRD, and how the combination of moxetumomab pasudotox and rituximab could alter the treatment landscape.

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

David H. Ilson, MD, PhD, discusses current treatment options for patients with gastric cancer, the challenges with the KEYNOTE-062 trial, and other immunotherapy agents coming down the pipeline.

Thomas Powles, MD, MBBS, MRCP, discusses the rationale for the BISCAY trial and what questions still need to be answered. 

Vincent Y. Ng, MD, discusses what implications the NEXIS study could have in soft tissue sarcoma treatment and the next steps going forward.

Leonard G. Gomella, MD, discusses the growth of genetic testing in prostate cancer, how to determine who should undergo testing, and what the future holds in this space.